Breaking Barriers: How Self-Administered Artesunate Confronts Cervical Cancer Stigma in Kenya

What Is This Trial About?

A pioneering Phase I clinical trial investigating self-administered intravaginal artesunate for cervical precancer in Western Kenya has uncovered critical insights into how stigma affects treatment adherence and participation. The study, conducted at Lumumba Sub-County Hospital in Kisumu County, revealed how women navigate complex social barriers while using innovative topical therapies that could help address the disproportionately high cervical cancer mortality rates in sub-Saharan Africa.

Why Is Cervical Cancer a Global Priority?

Cervical cancer remains the fourth leading cause of cancer deaths among women globally, with over 348,000 deaths annually. Low- and middle-income countries (LMICs) bear 94% of this mortality burden, with Eastern Africa recording incidence rates of 40.4 per 100,000 women-years—ten times higher than the World Health Organization's elimination target. The trial (NCT06165614) enrolled women with histologically confirmed cervical intraepithelial neoplasia 2/3 (CIN2/3) to self-administer 200mg artesunate pessaries nightly, five days weekly, in an alternating eight-week regimen. This approach represents a potential breakthrough in addressing key barriers to conventional ablative and excisional treatments, including limited access, painful procedures, high costs, and privacy concerns during pelvic examinations. The researchers conducted in-depth interviews with 17 participants to understand their experiences with stigma while self-administering treatment, using the Health Stigma and Discrimination Framework and a relational autonomy lens for analysis. Most participants were women living with HIV (88.2%), predominantly from low-income backgrounds, with 64.7% having primary education or less and 82% earning less than 500 KSH (approximately USD 4) daily.

How Does Stigma Impact Patient Experiences?

The study identified several interconnected stigma drivers, including patriarchal gender norms, taboos around sexual health discussions, and women bearing disproportionate burdens of HPV-related diseases. Poverty and limited healthcare access emerged as powerful facilitators of cervical precancer stigma, as unaffordable treatments led to worsening symptoms and cervical cancer deaths, intensifying community fears. Participants faced multiple stigma manifestations—anticipated stigma around partner rejection and intimate partner violence, enacted stigma through discrimination and prejudice, and internalized stigma manifested as anxiety that cervical precancer was a death sentence. One participant shared, "Most of the time you will hear news about cancer in last stages and if you get such news you just know that you are almost going for eternal rest." Another noted concerns about partner violence: "Like sometimes someone's partner is alcoholic... he wants to have sex with you whether you like it or not, but sometimes to avoid the beatings you will have to remove the tampon and drug is already inside working."

Despite these challenges, all participants successfully completed the treatment course. Many employed strategies reflecting relational autonomy, such as negotiating weeks of sexual intimacy with partners, seeking emotional support from family and peers, and finding strength through faith. Dr. Catherine Muthoni, the principal investigator and Kenyan-born obstetrician/gynecologist, emphasized that while self-administered treatments may reduce some stigma markers, such as fewer clinic visits, they don't eliminate stigma entirely. Women can still be 'marked' by aspects of topical therapies, including abstinence requirements and medication storage challenges. The research team noted that participants became advocates in their communities, initiating dialogues to destigmatize pelvic exams, encouraging screening, and even organizing informal women's savings groups to cover transportation costs to clinics. "Our main agenda is to create awareness of cancer screening and then seek treatment," stated one participant who successfully convinced others to get screened.

Can Self-Administered Artesunate Compete with Conventional Treatments?

The findings position artesunate as a potentially competitive alternative to conventional provider-administered treatments like thermal ablation and LEEP, especially in resource-limited settings. Unlike traditional excisional or ablative procedures requiring specialized equipment and trained providers, self-administered therapies offer greater privacy, convenience, and potentially lower costs—addressing critical access barriers in LMICs. The researchers recommend incorporating culturally informed counseling to address internalized stigmas, implementing IPV questionnaires in future studies, and developing community-based awareness programs with trained peer navigators.

What Does the Future Hold for Self-Administered Therapies?

Looking ahead, the research team plans to expand their investigations into how stigma influences abstinence requirements following existing treatments and further study stigmas specific to intravaginal treatments. They suggest that just as expanded access to antiretroviral therapy helped reduce HIV stigma, increasing access to treatments like self-administered artesunate, alongside greater public awareness, holds promise for reducing HPV and cervical precancer stigma.

How Are Social Insights Shaping Market Strategies?

Industry Context: This study exemplifies a growing trend in pharmaceutical development that integrates social determinants of health into clinical trial design and implementation. As companies increasingly recognize that drug efficacy depends not just on pharmacological action but on patient adherence and social context, we're seeing more investment in understanding cultural barriers to treatment. For women's health interventions in emerging markets, this approach is particularly crucial, as stigma and gender dynamics significantly impact care-seeking behaviors. The findings suggest that future therapeutic developments for conditions affecting women in LMICs will need to consider self-administration options and address social barriers to maximize market penetration and health impact.

Summary

A Phase I clinical trial in Western Kenya investigating self-administered intravaginal artesunate for cervical precancer has revealed significant insights into how stigma affects treatment adherence and participation among women. The study, conducted at Lumumba Sub-County Hospital in Kisumu County, enrolled women with histologically confirmed cervical intraepithelial neoplasia 2/3 who self-administered 200mg artesunate pessaries in an alternating eight-week regimen. Cervical cancer remains the fourth leading cause of cancer deaths among women globally, with low- and middle-income countries bearing 94% of the mortality burden and Eastern Africa recording incidence rates ten times higher than the World Health Organization's elimination target. The research identified multiple interconnected stigma drivers, including patriarchal gender norms, taboos around sexual health discussions, poverty, and limited healthcare access, which manifested as anticipated stigma around partner rejection, enacted stigma through discrimination, and internalized stigma expressed as anxiety about cervical precancer being a death sentence. Despite these challenges, all 17 participants, predominantly women living with HIV from low-income backgrounds, successfully completed the treatment course by employing strategies reflecting relational autonomy, such as negotiating sexual intimacy with partners, seeking emotional support, and finding strength through faith. The findings position self-administered artesunate as a potentially competitive alternative to conventional provider-administered treatments like thermal ablation and LEEP, offering greater privacy, convenience, and potentially lower costs that address critical access barriers in resource-limited settings. Participants became community advocates, initiating dialogues to destigmatize pelvic exams and encouraging screening, while researchers recommend incorporating culturally informed counseling, implementing intimate partner violence questionnaires, and developing community-based awareness programs with trained peer navigators in future studies. The research exemplifies a growing trend in pharmaceutical development that integrates social determinants of health into clinical trial design, recognizing that drug efficacy depends not just on pharmacological action but on patient adherence and social context, particularly crucial for women's health interventions in emerging markets where stigma and gender dynamics significantly impact care-seeking behaviors.